This article is more than 5 years old. Information may no longer be current.

Sun Pharma launches BromSite in US

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BromSite for the treatment of postoperative inflammation and prevention of ocular pain is now available in the United States, Sun Pharma announced in a press release.

BromSite (bromfenac ophthalmic solution 0.075%) was approved by the FDA on April 8 and is the first NSAID approved to prevent ocular pain and treat eye inflammation after cataract surgery, the release said. It is also the first branded product launched by Sun Pharma in the United States.

“Clinical studies have reinforced BromSite’s strong safety and efficacy profile in cataract surgery patients, culminating in this FDA indication for the prevention of ocular pain following surgery,” Abhay Gandhi, CEO, North America Business, Sun Pharma, said in the release. “We are confident BromSite will prove itself a quality treatment option for cataract surgeons and their patients.”